Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Study on cases of precocious puberty].

A Nanbu1, Y Kumamoto, Y Takagi

  • 1Department of Urology, Sapporo Medical College.

Hinyokika Kiyo. Acta Urologica Japonica
|October 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PAK1-deficiency/down-regulation reduces brood size, activates HSP16.2 gene and extends lifespan in Caenorhabditis elegans.

Drug discoveries & therapeutics·2013
Same author

From chemotherapy to signal therapy (1909-2009): A century pioneered by Paul Ehrlich.

Drug discoveries & therapeutics·2012
Same author

Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines.

Drug discoveries & therapeutics·2012
Same author

The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423.

Drug discoveries & therapeutics·2012
Same author

Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1.

Drug discoveries & therapeutics·2012
Same author

CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.

Phytotherapy research : PTR·2008

Medroxyprogesterone acetate (MPA) effectively treats idiopathic precocious puberty by suppressing hormones and slowing bone age, allowing for normal height growth. Treatment cessation is recommended between 11-13 years, coinciding with natural puberty onset.

Area of Science:

  • Pediatric Endocrinology
  • Reproductive Medicine

Background:

  • Idiopathic precocious puberty (IPP) involves early onset of puberty, leading to accelerated growth and bone maturation.
  • Management of IPP aims to halt progression, prevent psychosocial issues, and optimize adult height.
  • Medroxyprogesterone acetate (MPA) is a progestin used to suppress the hypothalamic-pituitary-gonadal axis.

Observation:

  • Three children (two boys, one girl) with IPP received MPA treatment for 2 years and 2 months to 9 years and 5 months.
  • Treatment monitored gonadotropin levels, pubertal signs and symptoms, and bone-age advancement.
  • Patient height was assessed for growth trajectory during the treatment period.

Findings:

  • MPA effectively suppressed elevated gonadotropin levels in patients with IPP.

Related Experiment Videos

  • Clinical signs and symptoms of precocious puberty were significantly reduced with MPA therapy.
  • MPA demonstrated a suppressive effect on bone-age advancement, contributing to near-normal height development.
  • The study suggests optimal treatment cessation for IPP is between 11-13 years of age.

    • Implications:

    • MPA is an effective therapeutic option for managing idiopathic precocious puberty.
    • Controlled bone-age progression with MPA supports achieving optimal adult height potential.
    • Establishing clear guidelines for MPA treatment duration is crucial for long-term patient outcomes.
    • Further research should explore long-term effects and optimal timing for treatment discontinuation.